Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events--Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment.
Warden
Diane
D
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9119, USA. Diane.Warden@UTSouthwestern.edu
Trivedi
Madhukar H
MH
Wisniewski
Stephen R
SR
Kurian
Benji
B
Zisook
Sidney
S
Kornstein
Susan G
SG
Friedman
Edward S
ES
Miyahara
Sachiko
S
Leuchter
Andrew F
AF
Fava
Maurizio
M
Rush
A John
AJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D008875:Middle Aged; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013405:Suicide / Q000523:psychology*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D017367:Selective Serotonin Reuptake Inhibitors
Curr Med Res Opin. 2006 Sep;22(9):1825-37
16968586
J Pharmacol Exp Ther. 1999 Dec;291(3):1179-87
10565840
Psychopharmacol Bull. 1986;22(2):343-81
3774930
Psychol Med. 2004 Jan;34(1):73-82
14971628
J Affect Disord. 2000 Apr;58(1):19-36
10760555
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
6080235
J Clin Psychopharmacol. 2000 Oct;20(5):523-30
11001236
Drug Alcohol Depend. 2007 May;88 Suppl 2:S61-71
17320312
Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):235-46
15073774
Pharmacopsychiatry. 2005 Mar;38(2):69-77
15744630
Clin Ther. 2000 Nov;22(11):1319-30
11117656
J Clin Psychiatry. 2005 Jul;66(7):859-63
16013901
Am J Psychiatry. 2003 Oct;160(10):1830-5
14514498
Health Educ Q. 1984 Spring;11(1):1-47
6392204
Ann Pharmacother. 2002 Apr;36(4):578-84
11918502
Arch Gen Psychiatry. 1999 Dec;56(12):1109-15
10591288
J Clin Psychiatry. 2003 Dec;64(12):1415-20
14728101
Br J Pharmacol. 2002 May;136(2):321-9
12010782
Eur J Pharmacol. 2001 Oct 5;428(2):235-40
11675041
Int J Neuropsychopharmacol. 2009 May;12(4):459-73
18611293
Neuropsychopharmacology. 2007 Dec;32(12):2479-89
17406651
Psychother Psychosom. 2009;78(6):372-9
19738403
Biol Psychiatry. 2003 Sep 1;54(5):573-83
12946886
Neuropsychopharmacology. 1999 Sep;21(3):455-66
10457543
Milbank Mem Fund Q. 1966 Jul;44(3):Suppl:94-127
5967464
Depress Anxiety. 2008;25(5):E1-8
17621644
Am J Psychiatry. 2007 Aug;164(8):1189-97
17671281
Clin Ther. 2003 Aug;25(8):2289-304
14512135
J Psychopharmacol. 1994 Jan;8(1):48-52
22298480
J Clin Psychiatry. 2001;62 Suppl 22:30-3
11599645
Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22-27
15014625
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):655-62
12512241
Gen Hosp Psychiatry. 2005 Jul-Aug;27(4):229-36
15993253
Med Care. 1992 Jan;30(1):67-76
1729588
Am J Psychiatry. 2006 Jan;163(1):28-40
16390886
Med Care. 1977 May;15(5 SUPPL):27-46
853780
Eur J Pharmacol. 2000 Sep 1;403(1-2):55-65
10969144
Eur J Pharmacol. 2000 Oct 27;407(1-2):39-46
11050288
J Clin Psychiatry. 2004 Jul;65(7):959-65
15291685
J Psychiatr Pract. 2006 Mar;12(2):71-9
16728903
Int Clin Psychopharmacol. 2008 Jan;23(1):36-42
18090506
Psychopharmacol Bull. 1994;30(2):151-6
7831448
J Clin Psychiatry. 1999 Jun;60(6):389-94
10401918
JAMA. 2002 Sep 18;288(11):1403-9
12234237